James T Sharkey1, Casey Cable, James Olcese. 1. Florida State University College of Medicine, Department of Biomedical Sciences, 1115 West Call Street, Tallahassee Florida 32306-4300, USA.
Abstract
CONTEXT: Studies have shown that labor occurs primarily in the night/morning hours. Recently, we identified the human myometrium as a target for melatonin (MEL), the neuroendocrine output signal coding for circadian night. OBJECTIVE: The purpose of this study was to determine the signaling pathway underlying the effects of MEL on contractility and the contractile machinery in immortalized human myometrial cells. DESIGN: To ascertain the signaling pathway of MEL leading to its effects on myometrial contractility in vitro, we performed gel retraction assays with cells exposed to iodo-MEL (I-MEL) with or without oxytocin and the Rho kinase inhibitor Y27632. I-MEL effects on inositol trisphosphate (IP(3))/diacylglycerol (DAG)/protein kinase C (PKC) signaling were also investigated. Additionally, we assayed for caldesmon phosphorylation and ERK1/2 activation. RESULTS: I-MEL was found to activate PKC alpha via the phospholipase C/IP(3)/DAG signaling pathway, which was confirmed by PKC enzyme assay. I-MEL did not affect myosin light chain phosphatase activity, and its effects on contractility were insensitive to Rho kinase inhibition. I-MEL did increase phosphorylation of ERK1/2 and caldesmon, which was inhibited by the MAPK kinase inhibitor PD98059 or the PKC inhibitor C1. CONCLUSIONS: MEL sensitizes myometrial cells to subsequent procontractile signals in vitro through activation of the phospholipase C/IP(3)/DAG signaling pathway, resulting in specific activation of PKC alpha and ERK1/2, thereby phosphorylating caldesmon, which increases actin availability for myosin binding and cross-bridging. In vivo, this sensitization would provide a mechanism for the increased nocturnal uterine contractility and labor that has been observed in late-term human pregnancy.
CONTEXT: Studies have shown that labor occurs primarily in the night/morning hours. Recently, we identified the human myometrium as a target for melatonin (MEL), the neuroendocrine output signal coding for circadian night. OBJECTIVE: The purpose of this study was to determine the signaling pathway underlying the effects of MEL on contractility and the contractile machinery in immortalized human myometrial cells. DESIGN: To ascertain the signaling pathway of MEL leading to its effects on myometrial contractility in vitro, we performed gel retraction assays with cells exposed to iodo-MEL (I-MEL) with or without oxytocin and the Rho kinase inhibitor Y27632. I-MEL effects on inositol trisphosphate (IP(3))/diacylglycerol (DAG)/protein kinase C (PKC) signaling were also investigated. Additionally, we assayed for caldesmon phosphorylation and ERK1/2 activation. RESULTS:I-MEL was found to activate PKC alpha via the phospholipase C/IP(3)/DAG signaling pathway, which was confirmed by PKC enzyme assay. I-MEL did not affect myosin light chain phosphatase activity, and its effects on contractility were insensitive to Rho kinase inhibition. I-MEL did increase phosphorylation of ERK1/2 and caldesmon, which was inhibited by the MAPK kinase inhibitor PD98059 or the PKC inhibitor C1. CONCLUSIONS:MEL sensitizes myometrial cells to subsequent procontractile signals in vitro through activation of the phospholipase C/IP(3)/DAG signaling pathway, resulting in specific activation of PKC alpha and ERK1/2, thereby phosphorylating caldesmon, which increases actin availability for myosin binding and cross-bridging. In vivo, this sensitization would provide a mechanism for the increased nocturnal uterine contractility and labor that has been observed in late-term human pregnancy.
Authors: L P Shearman; S Sriram; D R Weaver; E S Maywood; I Chaves; B Zheng; K Kume; C C Lee; G T van der Horst; M H Hastings; S M Reppert Journal: Science Date: 2000-05-12 Impact factor: 47.728
Authors: C Vandeputte; P Giummelly; J Atkinson; P Delagrange; E Scalbert; C Capdeville-Atkinson Journal: Am J Physiol Heart Circ Physiol Date: 2001-01 Impact factor: 4.733
Authors: Karl Swärd; Mitsuo Mita; David P Wilson; Jing Ti Deng; Marija Susnjar; Michael P Walsh Journal: Curr Hypertens Rep Date: 2003-02 Impact factor: 5.369
Authors: Jennifer Condon; Su Yin; Bobbie Mayhew; R Ann Word; W E Wright; J W Shay; William E Rainey Journal: Biol Reprod Date: 2002-08 Impact factor: 4.285
Authors: Shadab A Rahman; Carolina Bibbo; James Olcese; Charles A Czeisler; Julian N Robinson; Elizabeth B Klerman Journal: J Pineal Res Date: 2019-03-10 Impact factor: 13.007
Authors: Ronald McCarthy; Emily S Jungheim; Justin C Fay; Keenan Bates; Erik D Herzog; Sarah K England Journal: Front Endocrinol (Lausanne) Date: 2019-09-13 Impact factor: 5.555